Metformin attenuates cancer growth indirectly through reduction in serum insulin and IGF–1 concentration caused by improvement in insulin sensitivity, and directly through cell cycle arrest and inhibition of mammalian target of rapamycin (mTOR) following AMPK activation [19]. Here, PRKAA1 is linked to cancer.